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Abstract
Background: Investigations were conducted by the authors to explore an outbreak of viral hemorrhagic fever (VHF)
reported in 2010 from Al-Mukalla city, the capital of Hadramout in Yemen.
Methods: From 15–17 June 2010, the outbreak investigation period, specimens were obtained within 7 days after
onset of illness of 18 acutely ill patients hospitalized with VHF and 15 household asymptomatic contacts of 6 acute
cases. Additionally, 189 stored sera taken from acutely ill patients with suspected VHF hospitalized in the preceding
12 months were obtained from the Ministry of Health of Yemen. Thus, a total of 222 human specimens were
collected; 207 specimens from acute cases and 15 specimens from contacts. All samples were tested with RT-PCR
for dengue (DENV), Alkhumra (ALKV), Rift Valley Fever (RVFV), Yellow Fever (YFV), and Chikungunya (CHIKV) viruses.
Samples were also tested for DENV IgM, IgG, and NS1-antigen. Medical records of patients were reviewed and
demographic, clinical, and laboratory data was collected.
Results: Of 207 patients tested, 181 (87.4%) patients were confirmed to have acute dengue with positive dengue
NS1-antigen (97 patients, 46.9%) and/or IgM (163 patients, 78.7%). Of the 181 patients with confirmed dengue, 100
(55.2%) patients were IgG-positive. DENV RNA was detected in 2 (1%) patients with acute symptoms; both samples
were molecularly typed as DENV type 3. No other VHF viruses were detected. For the 15 contacts tested, RT-PCR
tests for the five viruses were negative, one contact was dengue IgM positive, and another one was dengue IgG
positive. Of the 181 confirmed dengue patients, 120 (66.3%) patients were males and the median age was 24 years.
The most common manifestations included fever (100%), headache (94.5%), backache (93.4%), malaise (88.4%),
arthralgia (85.1%), myalgia (82.3%), bone pain (77.9%), and leukopenia (76.2%). Two (1.1%) patients died.
Conclusions: DENV-3 was confirmed to be the cause of an outbreak of VHF in Al-Mukalla. It is important to use
both IgM and NS1-antigen tests to confirm acute dengue particularly under the adverse field conditions, where
proper storage and transportation of specimens are missing, which substantially reduce the sensitivity of the
RT-PCR for detecting DENV RNA.
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Background
The viruses that cause viral hemorrhagic fever (VHF) be-
long to four different families: Bunyaviridae, Flaviviridae,
Filoviridae, and Arenaviridae. Many countries of the
Middle East have experienced resurgent outbreaks of se-
veral VHFs including dengue virus (DENV), Rift Valley
Fever (RVF), Crimean-Congo Hemorrhagic Fever (CCHF),
and Alkhumra virus (ALKV) [1-7]. Additionally, Chikun-
gunya (CHIKV), a non-hemorrhagic acute mosquito-borne
viral illness that often mimics dengue fever, has caused out-
breaks in many Asian countries beyond its original bound-
aries in Africa [8]. Some of these VHFs are endemic in
the region [2]. Even though several studies have docu-
mented outbreaks and endemic transmission of dengue,
ALKV, RVF, and CCHF in Saudi Arabia, very scarce data
have been published on VHF in the neighboring coun-
try, Yemen [9-12].* Correspondence: tmadani@kau.edu.sa1Department of Medicine, Faculty of Medicine, King Abdulaziz University, PO
Box 80215, Jeddah 21589, Saudi Arabia
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In the period, 15–17 June 2010, investigations were
conducted by the authors to explore an outbreak of viral
hemorrhagic fever that was reported from Al-Mukalla
city, the capital of Hadramout in Yemen. This study
summarizes the results of this outbreak investigation.
Methods
The outbreak region: Al-Mukalla, Hadrahmout, Yemen
Hadramout is the largest governorate in the republic of
Yemen. It lies in the south of Yemen along the Gulf of
Aden in the Arabian Sea (15.9°N; 49°E) and extends
eastwards to the borders of Dhofar region of Oman. It
has a diverse topography with coastal plains along the
Arabian sea, mountains and hills reaching 2000 meters
above sea level, and the extensive desert of the empty
quarter, the largest sand desert in the world. Many val-
leys, known as wadis, run through Hadramout. The big-
gest of which is Wadi Hadramout which has several
branches. The climate in Hadramout is tropical hot in
the summer with temperatures up to 40°C. However, the
coastal area is moderate in temperature due to blow of
the humid monsoon trader winds with temperatures up
to 36°C. In the winter, the temperature drops to 20-24°C
in the coast and to 17-20°C in the interior parts. Al-
Mukalla, is the main Sea Port and the capital city of
Hadramout (14°32’N; 49°08’E). It is 480 km east of Aden
and 777 km from the capital Sanaa. It is the fourth lar-
gest city in Yemen, with an area of 193,032 km2. The
total population is approximately 300,000 people. Health
care facilities in the coastal plain of Hadramout include
13 hospitals and 25 primary health care centers.
Case definition
The case definition developed by Madani was adapted
to identify patients with VHF [5]. Viral hemorrhagic
fever was clinically suspected if a patient had an acute
febrile illness of at least 2 days duration and at least
2 of the following 5 clinical or laboratory criteria:
(1) headache, retro-orbital pain, arthralgia, myalgia,
bone pain, backache, or rash; (2) at least 3-fold
elevation of alanine transferase (AlT), or aspartate
transferase (AsT), or clinical jaundice; (3) features of
encephalitis such as confusion, disorientation, drow-
siness, coma, neck stiffness, hemiparesis, paraparesis,
or convulsions; (4) hemorrhagic manifestations such
as ecchymosis, purpura, petechiae, gastrointestinal
bleeding (hematemesis, melena, hematochezia), epi-
staxis, bleeding from puncture sites, or menorrhagia;
(5) leukopenia (white blood cells count < 4.5 × 109/L),
thrombocytopenia (platelet count < 100 x109/L), or
lactate dehydrogenase (LDH) or creatine phosphoki-
nase (CK) enzyme > 2 times upper normal level (>500
and >400 U/L, respectively).
Specimens obtained
As part of standard patient care, blood specimens were
collected within 7 days after onset of illness from all pa-
tients with clinically suspected VHF who were admitted
to hospitals in Al-Mukalla from 15–17 June 2010. Blood
was also collected from some of the household contacts
of the hospitalized patients after obtaining verbal in-
formed consents. Stored serum samples which were col-
lected in the preceding 12 months from acutely febrile
patients with suspected VHF were obtained from the
Ministry of Health of Yemen. The specimens were
transported in IATA compliant transport containers on
dry ice to the special Infectious Agents Units, a biosafety
level-3 virology laboratory, at King Fahad Medical
Research Centre, King Abdulaziz University, Jeddah,
Saudi Arabia.
Data collection
Medical records of patients hospitalized with clinically
suspected VHF were reviewed and data recorded on a
standard case report form. Information collected in-
cluded patient demographics, clinical manifestations, la-
boratory results, and outcome.
Laboratory confirmation
A simplified single-tube multiplex reverse transcriptase-
polymerase chain reaction (RT-PCR) was used to detect
dengue virus and determine its type as described by
Lanciotti et al. [13]. Briefly, 5 μl of extracted RNA were
added to 20 μl of an RT-PCR mixture consisting of 5 μl
of 5x QIAGEN One Step RT-PCR Buffer, 1 μl of
dNTPs, 1.0 μl of RT-PCR Enzyme Mix, 1 mM of the 5’
primer D1 and 3’ primers D2 and TS1, 0.5 mM of each
of the 3´ primers TS2, TS3, and TS4. Reverse transcrip-
tion was performed at 50°C for 30 minutes, followed
directly by 40 cycles of amplification consisting of 94°C
for 1 minute, 55°C for 1 minute, and 72°C for 1 minute,
ending with a final extension of 72°C for 10 minutes.
Ten μl of the product were analyzed by electrophoresis
in a 1.5% agarose gel in 1X Tris Borate EDTA (TBE)
buffer containing 4 ng/ml of ethidium bromide. The
expected size of the amplified products was as follows:
482 bp for dengue-1, 119 bp for dengue-2, 290 bp for
dengue-3, and 392 bp for dengue-4. Positive controls
for the RT-PCR included RNA extracted from tissue
culture isolates of different serotypes, which produces
an amplicon of 511 bp with primers D1 and D2 and
serves as an additional control for the molecular typing
of dengue amplification process. The human serum
samples were also tested with RT-PCR for ALKV,
RVFV, YFV, and CHIKV using previously described
methods [7,14,15].
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Detection of dengue IgM and IgG antibodies in the tested
sera
The human serum samples were tested for the presence
of dengue IgM and IgG antibodies employing capture
ELISA Kits (Dengue Duo IgM & IgG, Panbio, Australia)
as described by the manufacturer (http://panbiodengue.
com). The Panbio dengue early capture ELISA employing
the NS1- antigen (Inverness Medical Innovation Australia
Pty Ltd, Australia), was employed to detect the NS1 den-
gue virus antigen in the tested serum samples according
to the procedure described by the manufacturer.
Veterinary assessment of livestock
Many families in Hadramout keep sheep and goats in
the back-yards of their houses. There are also several
animal market places in the capital city, Al-Mukalla.
Blood specimens were randomly collected from animals
in the back-yards of the suspected human cases and
from other houses and market places. The animal spe-
cies were sheep and goats of different age groups. All
the animals were clinically examined by one of the au-
thors (EMEA, a professor of Veterinary Medicine and
Arbovirology) and the relevant epidemiological data was
collected from the animals’ owners. Sheep and goats sera
were tested with real time RT-PCR for detection of
RVFV, ALKV and CHIKV RNA as described above. King
Abdulaziz University's policy on the care and handling
of animals was followed.
Results
From 15–17 June 2010, the outbreak investigation period,
specimens were obtained within 7 days after onset of ill-
ness of 18 acutely ill hospitalized patients who fulfilled the
case definition for VHF and 15 household asymptomatic
contacts of 6 acute cases. Additionally, 189 stored sera
taken from acutely ill patients with suspected VHF hospi-
talized in the preceding 12 months were obtained from
the Ministry of Health of Yemen. Thus, a total of 222 hu-
man specimens were collected, of which 207 specimens
were from acute cases and 15 specimens were from con-
tacts. DENV RNA was detected in two samples from 2 pa-
tients with acute symptoms; one of them was a stored
specimen. Both of these two DENV-positive samples were
molecularly typed as DENV type 3. One of the two RNA-
positive patients was also NS1-antigen and IgM-positive,
whereas the other one was negative for both of them. RT-
PCR of the 222 human specimens was negative for ALKV,
RVFV, CHIKV, and YFV RNA.
Table 1 shows the results of the RT-PCR for detection
of DENV RNA and ELISA for detection of DENV NS1-
antigen, IgM and IgG. Of 207 acute cases tested, 181
(87.4%) patients were confirmed to have acute dengue
with positive dengue NS1-antigen and/or IgM. Ninety
seven (46.9%) patients were positive for DENV NS1-
antigen, and 163 (78.7%) patients were positive for
DENV IgM. Of the 181 patients with confirmed dengue,
100 (55.2%) patients were IgG-positive. Table 2 summa-
rizes the details of the diagnostic laboratory results
among the 181 patients with confirmed dengue. Of the
97 patients with positive NS1-antigen, 79 (81.4%) pa-
tients were also positive for IgM. Of the 163 patients
who were positive for IgM, 79 (48.5%) patients were also
positive for NS1-antigen.
Of the 181 confirmed cases, 120 (66.3%) patients were
males. The mean age was 21 ± 12 (range: 3–75) years
and the median was 24 years. Table 3 shows the clinical
and laboratory manifestations of the 181 patients with
confirmed acute dengue fever. Two (1.1%) patients died
of complicated dengue infection.
Forty seven goats and 6 sheep were clinically examined
and found to be healthy. Sera from these animals were
negative for the presence of RNA for ALKV, RVFV, and
CHIKV.
Discussion
The historic record of dengue infection in Yemen goes
back to the 19th century when a severe outbreak was
reported in 1870 – 1873 [1]. In 1954 a dengue epidemic
Table 1 RT-PCR for dengue virus RNA and ELISA results for detection of dengue virus NS1, IgM and IgG antibodies in


























No. of patients positive for IgM, IgG, or both (%)
IgM alone (%) IgG alone (%) IgG & IgM (%)
Acute cases 207 2 (1) 97 (46.9)* 169 (81.6) 69 (33.3)† 6 (2.9)‡ 94 (45.4)§
Contacts 15 0 0 2 (13.3) 1 (6.7) 1 (6.7) 0
* Of these 97 NS1-positive patients, 79 (81.4%) patients were also positive for IgM.
† Of these 69 IgM-positive patients, 50 (72.5%) patients were also NS1-positive.
‡ Considered to have acute dengue and past exposure to another dengue serotype based on positive NS1 and IgG.
§ Of these 94 IgM/IgG-positive patients, 29 (30.9%) patients were also NS1-positive.
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was also reported in Yemen, when 98% of the population
in Alhudaydah was affected [1]. In 1983 a patient who
had recently returned from South Yemen to the United
Stated was confirmed to have dengue infection [16]. In
2003, a survey on 158 blood specimens from 158 febrile
patients and 716 blood specimens from apparently
healthy individuals, from various localities in Yemen,
showed that all specimens were negative for dengue IgM
and IgG [17]. In 2010, an Italian patient who had
returned from Yemen to Italy was confirmed to have
contracted dengue infection [18]. Interestingly, that pa-
tient acquired the infection from Al-Mukalla and the
serotype was also DENV-3. Several other official reports
described outbreaks of dengue in various localities of
Yemen (unpublished data, Ministry of Health, Yemen).
DENV-3 was confirmed to be the cause of the dengue
outbreak described herein. Sequencing of the two posi-
tive samples, intended to be performed by the authors in
the near future, will provide phylogenetic and epidemio-
logical information about the virus.
The four distinct serotypes of DENV (DENV-1, DENV-
2, DENV-3 and DENV-4) don’t cross-protect, but infec-
tion with one serotype gives life-long immunity against its
homologous challenging field virus, i.e. the four serotypes
are cross-reacting but not cross-neutralizing. In this study,
more than half (55.2%) of the patients with acute dengue
had serological evidence (positive for DENV IgG) of previ-
ous exposure to this virus suggesting that more than one
serotype are circulating in the region, thus increasing
the risk of complicated dengue through a phenomenon
known as antibody-dependent enhancement or immune
enhancement syndrome [19-21]. It should be noted that
some of the IgG positive results of the 181 patients with
acute dengue might have represented early development
of IgG response at the end of the first week of acute den-
gue infection rather than previous exposure to another
dengue serotype.
Rapid and early laboratory diagnosis of dengue infec-
tion is a pivotal step towards monitoring of the cases
and earlier implementation of supportive therapy to pre-
vent mortality from dengue haemorrhagic fever and den-
gue shock syndrome. The three rapid diagnostic tests
currently available are: the RT-PCR, which can detect
the dengue RNA within 1–5 days after onset of fever;
the detection of the dengue virus non-structural protein
1 (NS1-antigen) within 1–9 days after onset of fever; and
IgM detection at least 5–7 days after onset of fever.
Therefore, RT-PCR and NS1-antigen tests can be diag-
nostic before IgM sero-conversion. The NS1-antigen is a
46–50 Kilo Dalton (K Da) glycoprotein found in dengue
virus-infected cells in two forms: membrane associated
(mNS1) and secreted (sNS1) form. Detection of the
(sNS1) at high levels in plasma and sera of dengue pa-
tients was found to correlate well with viraemia level
and the type of clinical dengue manifestations [22]. It
was also found that (sNS1) was higher in patients who
developed dengue hemorrhagic fever compared to those
who developed classic dengue fever [22].
In this study, the use of NS1-antigen test identified
53.6% of the confirmed cases, whereas IgM test identi-
fied 90% of them. The use of NS1-antigen test identified
18.6% of patients who would have been missed if IgM
test alone (without NS1-antigen test) were used to con-
firm acute dengue, whereas the use of IgM test identified
Table 2 Dengue NS1, IgM, and IgG results of 181 patients




Laboratory result Number of
patients (%)NS1 IgM IgG
1 + + - 50 (27.6)
2 + - - 12 (6.6)
3 - + - 19 (10.5)
4 + + + 29 (16.0)
5 + - + 6 (3.3)
6 - + + 65 (35.9)
Total number (%) 97 (53.6) 163 (90.0) 100 (55.2) 181 (100)
Table 3 Clinical and laboratory features of 181 patients
with laboratory-confirmed dengue fever in Al-Mukalla,
Yemen, 2009-2010







Bone pain 141 (77.9)
Leukopenia 138 (76.2)
Anorexia 112 (61.9)




Abdominal pain 34 (18.9)
Hemorrhagic manifestations 14 (7.7)
Rash 9 (5.0)
Central nervous system manifestations 3 (1.7)
Altered sensorium 3 (1.7)
Neck stiffness 2 (1.1)
Convulsions 1 (0.6)
Jaundice 2 (1.1)
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51.5% of patients who would have been missed if NS1-
antigen test alone (without IgM test) were used to con-
firm acute dengue. The RT-PCR identified only 1.0% of
the confirmed cases. This was most likely due to degrad-
ation of RNA during storage and shipping.
Conclusions
DENV-3 was confirmed to be the cause of an outbreak
of VHF in Al-Mukalla, Hadramout, Yemen in 2010.
More than half of the affected patients had evidence of
previous exposure to DENV indicating that more than
one serogroup were circulating in the region. It is im-
portant to use both IgM and NS1-antigen tests to con-
firm acute dengue particularly under the adverse field
conditions, where proper storage and transportation of
specimens are missing, which substantially reduce the
sensitivity of RT-PCR for detecting DENV RNA.
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